What does Remopharma do?

Remopharma is a pharmacy in Sint-Gillis-Waas. Private Limited, started on 24 September 2008, 5 establishments.

What is the address of Remopharma?

The registered office of Remopharma is located at Meerdonkdorp(MD) 24, 9170 Sint-Gillis-Waas.

Is Remopharma still active?

Yes. According to the CBE (2 November 2026) Remopharma is active, legal situation “Normale toestand”, started on 24 September 2008.

Is Remopharma registered on Peppol?

Yes, Remopharma is registered on the Peppol network with ID 0208:0806560542.

What is the enterprise number of Remopharma?

The enterprise number of Remopharma is BE0806560542.

When was Remopharma founded?

Remopharma was founded on 24 September 2008.

Who are the directors of Remopharma?

According to the 2025 annual accounts, the directors of Remopharma are: Christel Van Remoortel, Pieter Leys.

Is Remopharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 24 September 2008; 3 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 5 establishments in the CBE.

How much profit did Remopharma make in 2025?

Remopharma posted a profit after taxes of € 241,142 in financial year 2025.

What is the revenue of Remopharma?

As a small company, Remopharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,102,250.

How much does an employee at Remopharma earn?

The average wage cost per full-time employee at Remopharma was € 65,100 in 2025: staff costs of € 455,871 for 7 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Remopharma have?

According to the 2025 annual accounts, Remopharma has 7 full-time equivalents (FTE).

Does Remopharma have a website?

Yes, Remopharma has a website at remopharma.be.

Remopharma (Private Limited) - Sint-Gillis-Waas

Dossier Remopharma, printed on 2 November 2026 from databakkes.be/en/0806560542/remopharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Remopharma from Sint-Gillis-Waas, company number BE0806560542, closed financial year 2025 with a result of € 241,142 after tax. For that financial year Remopharma recorded a gross margin of € 1.1 million and equity of € 2.2 million. Compared with financial year 2024, the result moved from € 295,595 to € 241,142. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 18, 2026.

What it is worth Growing

€ 2.2 million

▲ 12% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 241,142

▼ 18% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 233,124

▲ 20% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 2.2 million.

People and assets in 2025

Full-time equivalents

▲ 0.9 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 455,871

▲ 38% vs 2024

€ 65,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 16,562

▼ 9% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 754,104

▼ 11% vs 2024

€ 124,793 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 628,904

▲ 41% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 73,891

▲ 50% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 932,226 Gross margin 2023: € 932,226 First fiscal year in the series	€ 965,347 Gross margin 2024: € 965,347 ▲ 4% vs 2023 (€ 932,226) Favourable step	€ 1,102,250 Gross margin 2025: € 1,102,250 ▲ 14% vs 2024 (€ 965,347) Favourable step	▲ 14%
Profit after taxes	€ 304,120 Profit after taxes 2023: € 304,120 First fiscal year in the series	€ 295,595 Profit after taxes 2024: € 295,595 ▼ 3% vs 2023 (€ 304,120) Unfavourable step	€ 241,142 Profit after taxes 2025: € 241,142 ▼ 18% vs 2024 (€ 295,595) Unfavourable step	▼ 18%
Equity	€ 1,668,423 Equity 2023: € 1,668,423 First fiscal year in the series	€ 1,964,018 Equity 2024: € 1,964,018 ▲ 18% vs 2023 (€ 1,668,423) Favourable step	€ 2,205,160 Equity 2025: € 2,205,160 ▲ 12% vs 2024 (€ 1,964,018) Favourable step	▲ 12%
Total debts	€ 1,582,385 Total debts 2023: € 1,582,385 First fiscal year in the series	€ 1,347,529 Total debts 2024: € 1,347,529 ▼ 15% vs 2023 (€ 1,582,385) Favourable step	€ 1,458,273 Total debts 2025: € 1,458,273 ▲ 8% vs 2024 (€ 1,347,529) Unfavourable step	▲ 8%
Cash	€ 252,574 Cash 2023: € 252,574 First fiscal year in the series	€ 194,009 Cash 2024: € 194,009 ▼ 23% vs 2023 (€ 252,574) Unfavourable step	€ 233,124 Cash 2025: € 233,124 ▲ 20% vs 2024 (€ 194,009) Favourable step	▲ 20%
Land & buildings	€ 1,192,673 Land & buildings 2023: € 1,192,673 First fiscal year in the series	€ 1,128,351 Land & buildings 2024: € 1,128,351 ▼ 5% vs 2023 (€ 1,192,673) Unchanged	€ 1,162,576 Land & buildings 2025: € 1,162,576 ▲ 3% vs 2024 (€ 1,128,351) Unchanged	▲ 3%
Retained profit	€ 1,667,423 Retained profit 2023: € 1,667,423 First fiscal year in the series	€ 1,963,018 Retained profit 2024: € 1,963,018 ▲ 18% vs 2023 (€ 1,667,423) Favourable step	€ 2,204,160 Retained profit 2025: € 2,204,160 ▲ 12% vs 2024 (€ 1,963,018) Favourable step	▲ 12%
Bank debt	€ 981,638 Bank debt 2023: € 981,638 First fiscal year in the series	€ 848,900 Bank debt 2024: € 848,900 ▼ 14% vs 2023 (€ 981,638) Favourable step	€ 754,104 Bank debt 2025: € 754,104 ▼ 11% vs 2024 (€ 848,900) Favourable step	▼ 11%
Balance sheet total	€ 3,250,808 Balance sheet total 2023: € 3,250,808 First fiscal year in the series	€ 3,311,547 Balance sheet total 2024: € 3,311,547 ▲ 2% vs 2023 (€ 3,250,808) Unchanged	€ 3,663,433 Balance sheet total 2025: € 3,663,433 ▲ 11% vs 2024 (€ 3,311,547) Unchanged	▲ 11%
Employees (FTE)	5.3 Employees (FTE) 2023: 5.3 First fiscal year in the series	6.1 Employees (FTE) 2024: 6.1 ▲ 0.8 vs 2023 (5.3) Unchanged	7 Employees (FTE) 2025: 7 ▲ 0.9 vs 2024 (6.1) Unchanged	▲ 0.9

Key figures of Remopharma, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Remopharma?

What happened at Remopharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 18, 2026 New annual accounts for financial year 2025: profit of € 241,142 (▼ 18% vs 2024). filed late Source: NBB ↗
Mar 19, 2026 New establishment in Sint-Gillis-Waas. KBO
Dec 31, 2021 New establishment in Beveren-Kruibeke-Zwijndrecht. KBO
2021 Pieter Leys became a director. NBB
Dec 23, 2018 New establishment in Sint-Niklaas. KBO
Jan 1, 2011 New establishment in Beveren-Kruibeke-Zwijndrecht. KBO
Oct 1, 2008 New establishment in Sint-Gillis-Waas. KBO
Sep 24, 2008 Start of the company according to the CBE. KBO

In short

From € 304,120 profit in 2023 to € 241,142 profit in 2025.

Paid € 270,562 in corporate taxes since 2023.

Best year ever: 2023, with € 304,120 profit.

On average € 157,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Christel Van Remoortel Pieter Leys

Remopharma

Behind Remopharma are Christel Van Remoortel and Pieter Leys.

Directors

According to the 2025 annual accounts

Christel Van Remoortel

Statutaire Bestuurder

since 2008

Pieter Leys

Statutaire Bestuurder

since 2021

Establishments

Establishment units

Physical locations of this company

Registered office

Meerdonkdorp(MD) 24

9170 Sint-Gillis-Waas

2.203.885.332

Hoog-Kallostraat(KAL) 22A

9120 Beveren-Kruibeke-Zwijndrecht

Active since 1 January 2011

2.326.956.358

Marktstraat 23

9111 Sint-Niklaas

Active since 23 December 2018

2.326.956.457

Kieldrechtsebaan(VER) 6A

9130 Beveren-Kruibeke-Zwijndrecht

Active since 31 December 2021

2.389.088.620

Sint-Gillisstraat(DKL) 16

9170 Sint-Gillis-Waas

Active since 19 March 2026

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

VME gebouw "RESIDENTIE PHARMA" Meerdonkdorp 24, te 9170 St.Gillis-Waas (Meerdonk)

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS remopharma.be

Technologies

BootstrapChart.jsCloudflare CDNDiviElementorFont AwesomeGoogle FontsGravity FormsOwl CarouselPHPWooCommerceWordPressYoast SEOjQueryjQuery UIlazysizesreCAPTCHA

Hosting & Email

Email provider

Self-hosted

Hosting

CLOUDFLARENET - Cloudflare, Inc., US

DNS

Cloudflare DNS

Website info

HTTPS Ja

Languages EN

Features

Webshop Blog Client portal Contact page

Security

✓ HTTPS

✓ SPF

✗ DMARC

Network

✓ IPv6

✓ Load balancing

Details

Company number: 0806.560.542
VAT number: BE 0806.560.542
Registered office: Meerdonkdorp(MD) 24, 9170 Sint-Gillis-Waas
Names & denominations: Remopharma
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 24 September 2008
Peppol: Active · Active since 27 Sept 2024
Contact: remopharma.be
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗